COVER LETTER

1. MAIN AUTHOR: Marta Domínguez Morcillo, MD; Department of Radiation Oncology, Hospital Central de la Defensa, Universidad de Alcalá de Henares, Madrid, Spain.
2. CONTRIBUTING AUTHORS:
   1. Carmen Ibáñez Villoslada; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
   2. Joaquín Navarro Castellón; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
   3. Paula Sáez Bueno; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
   4. Eliseo Carrasco Esteban; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
   5. Andrea Matas Escamillas; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
   6. Zigor Zalabarría Zarrabeitia; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
   7. María Concepción López Carrizosa; MD; Department of Radiation Oncology, Hospital Central de la Defensa, Madrid, Spain.
3. IMPORTANCE OF THE PUBLICATION: To demonstrate that low dose rate brachytherapy in monotherapy in an excellent curative option for patients with low-risk prostate cancer, with which we obtain very good local and biochemical control rates. We have shown that there is a relationship between the dose received by 90% and 100% of the prostate gland and the development of local and biochemical failure.
4. DECLARATION: I, Marta Domínguez Morcillo, declare authorship of this work.
5. CONFLICT OF INTERESTS: in this study, there has been no conflict of interest or funding by any entity.
6. CONTRIBUTION: All participants have contributed by updating and including data for the study in our database. María Concepción López Carrizosa (editor of the journal) has directed this work.